Skip to main content

Table 1 Patient background and disease-related characteristics collected at time of inclusion

From: Breastfeeding in women with systemic lupus erythematosus: results from a Norwegian quality register

Number of included women with SLE in the study

N = 114

Age mean (SD)

31.1 (4.7)

Age ≥ 35 yrs (%)

30 (26.3)

Parity n (%)

 0

64 (56.1)

 1

34 (29.8)

  ≥ 2

16 (14.0)

Smoking / snuff tobacco

3 (2.6)

BMI kg/m2 n(%)

 Underweight (< 18.5 kg/m2)

4 (4.0)

 Normal weight (18.5–24.9 kg/m2)

61 (61.6)

 Overweight (≥ 25 kg/m2)

34 (34.5)

Regular physical activity (%)a

51.0

Educational levels (%)b

 Low

6.4

 Intermediate

22.0

 High

71.6

Working fulltime or part-time (%)

66.4

Disease related characteristics

Disease duration in years mean (SD)

7.6 (5.5)

CRP mean (SD)

3.6 (5.0)

 CRP value > 5 mg/L (%)

16.2

Anti-phospholipid antibodies present n (%)

30 (29.1)

ANA/ENA CTD screening positive n (%)

87 (81.3)

Inflammatory active disease n (%)c

 No /low disease activity

87 (88.8)

 Moderate disease activity

10 (10.2)

 High disease activity

0

Medications

 HCQ

85 (74.6)

 sDMARDsd

34 (29.8)

 bDMARDse

1 (0.9)

  1. BMI body mass index, CRP C-reactive protein, ANA anti-nuclear antibodies, ENA extractable nuclear antigens, SD standard deviation, CTD connective tissue disease, HCQ hydroxychloroquine, sDMARDs synthetic disease modifying anti-rheumatic drugs, bDMARDs biologic disease modifying anti-rheumatic drugs
  2. aat least once weekly
  3. beducational level: low = elementary school, medium = high school/vocational education, high = college/university
  4. cmeasured by LAI-P/SLEDAI. Active disease: ≥ 2,2 (LAI-P) or > 6 (SLEDAI)
  5. dsDMARDs included azathioprine, methotrexate, sulphasalazine and mycophenolate mofetil
  6. ebDMARDs included belimumab, TNF-inhibitors and interleukin inhibitors